Advised by MAS Capital, Suntec Medical Plans for a US$100M Nasdaq IPO in 2027 [Yahoo! Finance]
Bicara Therapeutics Inc. (BCAX)
Company Research
Source: Yahoo! Finance
Advised by MAS Capital, Suntec is under discussion with VCs for a US$25 million Series A private placement, which the Company expects to complete in Q3 2026. Suntec is seeking funding to expedite the clinical trials of its four drug candidates. Earlier this month MAS Capital proposed to make a strategic investment in Suntec. According to Ms. Rebecca Shih, strategic advisor to Suntec, "We believe with MAS Capital's professional investment banking experience and capabilities, Suntec will successfully achieve its financial and clinical trial goals in a timely manner!" Suntec has patented a revolutionary MINC Technology to develop new multi-target immunotherapies able to penetrate BBB (blood-brain barrier) into the brain to treat challenging CNS (central nervous system) diseases with high efficacy, high response rate and low toxicity. Suntec has developed four breakthrough, First-in-class and Best-in-class new therapies for Alzheimer's & Parkinson's diseases, Stroke/TBI (Traumatic Brain
Show less
Read more
Impact Snapshot
Event Time:
BCAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCAX alerts
High impacting Bicara Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BCAX
News
- Bicara Therapeutics (BCAX) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- A Look At Bicara Therapeutics (BCAX) Valuation After Earnings Losses And New Shelf Registration [Yahoo! Finance]Yahoo! Finance
- Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement [Seeking Alpha]Seeking Alpha
BCAX
Earnings
- 3/30/26 - Beat
BCAX
Sec Filings
- 4/22/26 - Form 4
- 4/21/26 - Form 144
- 4/20/26 - Form 4
- BCAX's page on the SEC website